Key Takeaway: Indivior reported strong financial results for the second quarter of 2026, with total net revenue reaching $343 million, a 14% increase compared to the previous year. The company's SUBLOCADE® product achieved record net revenue of $253 million, reflecting a 21% year-over-year growth. Additionally, both GAAP and non-GAAP net income reached record levels, indicating robust financial performance.
Price reaction · baseline $40.01 (2026-07-31 close) · hit pre-market · clean, no other INDV news in the window
day 0 close
-6.6%
day 1 · peak
-8.8%
day 3
-3.3%
Market Sentiment Analysis
POSITIVE FACTORS
Total net revenue increased by 14% year-over-year.
Record net revenue for SUBLOCADE® at $253 million.
GAAP net income reached a record of $122 million.
Adjusted EBITDA also set a record at $186 million.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+35%
120-day peak, hindsight
Typical move
5.4%
average across 2 past catalysts
Lead asset
RBP-6000
Phase 3 · Opioid Use Disorder
Full Press Release Details
• Q2’26 Total Net Revenue of $ 343 Million, Up 14% YoY • Record Quarterly Total SUBLOCADE® Net Revenue of $ 253 Million in Q2'26, Up 21% YoY • Record Quarterly GAAP Net Income of $122 Million and Record Non-GAAP Net Income of $142 Million in Q2'26 • Record Quarterly Adjusted EBITDA of $ 186
Frequently Asked Questions
What was Indivior's total net revenue for Q2 2026?
Indivior's total net revenue for Q2 2026 was $343 million.
How much did SUBLOCADE® earn in Q2 2026?
SUBLOCADE® generated record net revenue of $253 million in Q2 2026.
What was the GAAP net income for Indivior in Q2 2026?
Indivior reported a GAAP net income of $122 million for Q2 2026.
What is the adjusted EBITDA for Indivior in Q2 2026?
The adjusted EBITDA for Indivior in Q2 2026 was $186 million.